Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Consequently antisense ATM gene therapy could serve as a paradigm for strategies that target the cellular survival mechanisms of an irradiated tumor cell and may provide therapeutic benefit to patients undergoing radiation therapy for PC.
|
11059687 |
2000 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
AT(1) receptor expression in human prostate cancer tissue was higher (9 of 10 cases) than that in normal prostate tissue.
|
14617787 |
2003 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These results provide evidence that the presence of common variants in the ATM gene, may confer an altered cellular phenotype, and that the ATM 3161C>G variant might be associated with prostate cancer risk.
|
15280931 |
2004 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
To investigate angiotensin II type 1 (AT1) receptor expression in prostate cancer tissue, real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was performed, using specimens, from untreated patients with prostate cancer.
|
16369744 |
2005 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
These data suggest that the CS pathway initiates a generic mode of radiation-induced apoptosis in human prostate cancer cells, regulated by a suppressive function of ATM, and that ATM might represent a potential target for pharmacologic inactivation with potential clinical applications in human prostate cancer.
|
15837784 |
2005 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer.
|
15629612 |
2005 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
To test this idea, we knocked down ataxia telangiectasia mutated (ATM) gene by RNA interference in prostate cancer cell lines and in normal human diploid fibroblasts IMR90.
|
15805289 |
2005 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Underexpression of ATDC in breast and prostate cancer has been reported using serial analysis of gene expression (SAGE) and DNA microarray analysis.
|
16890201 |
2006 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Radiation reaction and radiation sensitivity contribute to ED and greater LUTS in men who have had brachytherapy for prostate cancer.This contribution is evident, e.g. in men with ataxia-telangiectasia (ATM) gene mutations.
|
17034599 |
2006 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Grape seed extract induces anoikis and caspase-mediated apoptosis in human prostate carcinoma LNCaP cells: possible role of ataxia telangiectasia mutated-p53 activation.
|
16731759 |
2006 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The results of our study indicate that this ATM polymorphism is not associated with the aggressiveness of prostate cancer in white men.
|
16765197 |
2006 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The ATM missense variant P1054R confers an about twofold increased risk for prostate cancer in our series.
|
17502119 |
2007 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The possession of genetic variants in the ATM gene is associated with the development of radiation-induced proctitis after prostate cancer radiotherapy for patients who receive the full prescription dose to either a low or a moderate volume of rectal tissue.
|
17490827 |
2007 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
This review provides an insight into the key role of Ang-II and the AT1 receptor, and the possibility of ARBs for molecular targeting of mitogenesis and angiogenesis in prostate cancer.
|
18184167 |
2008 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Multifactorially adjusted hazard ratios for ATM Ser49Cys heterozygotes versus noncarriers were 1.2 (95% CI, 0.9 to 1.5) for cancer overall, 0.8 (95% CI, 0.3 to 2.0) for breast cancer, 4.8 (95% CI, 2.2 to 11) for melanoma, 2.3 (95% CI, 1.1 to 5.0) for prostate cancer, and 3.4 (95% CI, 1.1 to 11) for cancer of the oral cavity/pharynx.
|
18565893 |
2008 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A missense variant in ATM, rs1800057, associated with increased prostate cancer risk, was found exclusively in two high toxicity patients but did not reach statistical significance for association with radiosensitivity (P = 0.488).
|
19638463 |
2009 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We previously demonstrated that treatment of human androgen-responsive prostate cancer cell lines LNCaP and CWR22-Rv1 with 12-O-tetradecanoylphorbol 13-acetate (TPA), a known protein kinase C (PKC) activator, decreases ATM protein levels, thus de-repressing the enzyme ceramide synthase (CS) and promoting apoptosis as well as radio-sensitizing these cells.
|
19029835 |
2009 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Colony formation assay was used to assess the sensitivity of hormone dependent, p53 wt (LNCaP) and hormone independent p53 mutant (PC3) CaP cell lines to the cytotoxic effect of IR and Doxorubicin in the presence or absence of Ku55933 and NU7441 which are small molecule inhibitors of ATM and DNA-PK, respectively.
|
21629734 |
2011 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Substantial fraction of information has been added into the existing literature of ATM biology; however, the particular area of post-transcriptional processing errors and gene therapy for reprogramming of ATM has been left unaddressed in prostate cancer.
|
22200977 |
2012 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Functional activation of ATM by the prostate cancer suppressor NKX3.1.
|
23890999 |
2013 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining in human PCa tissue microarrays revealed ATM expression is highly correlated with TR4 expression.
|
24583925 |
2014 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In addition, it was recently shown that aberrations in DNA repair genes, such as BRCA2 and ATM, are present in both somatic and germline form in a significant minority of prostate cancer; these abnormalities can be targeted by drugs such as platinums and PARP inhibitors.
|
26210103 |
2015 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
|
27443449 |
2016 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prostate cancer patients with inherited mutations in BRCA1/2 and ATM are more likely to die of prostate cancer and do so at an earlier age.
|
27989354 |
2017 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.
|
29659569 |
2018 |